Summary by Moomoo AI
GSK announced positive results from ANCHOR-1 and ANCHOR-2 phase III trials evaluating depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials met primary endpoints, demonstrating significant reduction in nasal polyp size and nasal obstruction versus placebo at 52 weeks. The safety profile was comparable between treatment and placebo groups.Depemokimab, an ultra-long-acting biologic administered once every six months, targets IL-5, a key protein in type 2 inflammation present at high levels in nasal polyp tissue. The treatment could benefit up to 4% of the general population affected by CRSwNP, of whom 40% have uncontrolled disease and up to 80% show evidence of type 2 airway inflammation.The company plans to use these results, along with recent positive phase III data in severe asthma, for regulatory filings worldwide. The extended dosing interval of six months could potentially reduce clinic visits and minimize missed doses, offering a new treatment option for patients who often require corticosteroids and face high risk of polyp recurrence after surgery.
